Effect of glucagon-like peptide-1 (GLP-1) agonists on the example of semaglutide on the cardiovascular system and their role in the treatment of obesity.
Keywordsobesity, weight loss, GLP-1 agonists, cardiovascular risk
Obesity nowadays affects an increasing number of people. We can talk about it when the patient's BMI is ≥ 30.0 kg/m² (BMI 25.0-29.9 kg/m² - overweight). While obesity in itself may not be a problem for people suffering from it, its complications can be global and sometimes pose a serious threat to health or even life. Its main complications in the cardiovascular system include: hypercholesterolaemia, arterial hypertension, left ventricular hypertrophy, early atherosclerotic changes, heart and cerebral infarction. Treatment of obesity is based mainly on changing the patient's lifestyle - diet and physical activity, which can sometimes be problematic and difficult to apply.
However, there is a new group of hypoglycaemic drugs - glucagon-like peptide-1 (GLP-1) agonists, which can make obesity treatment easier. These drugs use the incretin effect in the body to increase insulin secretion in response to a meal containing carbohydrates and prevent postprandial hyperglycemia. In this article, we will analyze the latest studies on the effects of GLP-1 receptor agonists, using semaglutide as an example, on the cardiovascular system and on weight loss in patients.
Obesity and overweight, www.who.int [accessed 13.08.2022]
Complications of obesity in children and adolescents. Aneta Gawlik, Agnieszka Zachurzok-Buczyńska, Ewa Małecka-Tendera Department of Pediatrics, Endocrinology and Pediatric Diabetology, Medical University of Silesia in Katowice
Volkan Yumuk i inni, European Guidelines for Obesity Management in Adults, „Obesity Facts”, 8 (6), 2015, s. 402–424
Ewa Szczepańska, Progress in obesity treatment, "Postępy Nauk Medycznych", 28 January 2008 [accessed on August 13, 2022]
Characteristics of the medicinal product – Ozempic, INN-semaglutide
Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis. Ping Zhong, Hai Zeng, Miaochun Huang, Wenbin Fu & Zhixia Chen, Endocrine volume 75, pages 718–724 (2022)
Clinical review of subcutaneous semaglutide for obesity. Anna Phillips PharmD Candidate, Jennifer N. Clements PharmD, FCCP, FADCES, BCPS, CDCES, BCACP, BC-ADM
Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes. The STEP 8 Randomized Clinical Trial. Domenica M. Rubino, MD; Frank L. Greenway, MD; Usman Khalid, MD, PhD
Aaron E. Carroll, To Lose Weight, Eating Less Is Far More Important Than Exercising More, „The New York Times”, 15 June 2015, ISSN 0362-4331
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes Steven P. Marso, M.D., Stephen C. Bain, M.D., Agostino Consoli, M.D., Freddy G. Eliaschewitz, M.D., Esteban Jódar, M.D., Lawrence A. Leiter, M.D., Ildiko Lingvay, M.D., M.P.H., M.S.C.S., Julio Rosenstock, M.D., Jochen Seufert, M.D., Ph.D., Mark L. Warren, M.D., Vincent Woo, M.D., Oluf Hansen, M.Sc., et al., for the SUSTAIN-6 Investigators
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mansoor Husain, M.D., Andreas L. Birkenfeld, M.D., Morten Donsmark, Ph.D., Kathleen Dungan, M.D., M.P.H., Freddy G. Eliaschewitz, M.D., Denise R. Franco, M.D., Ole K. Jeppesen, M.Sc., Ildiko Lingvay, M.D., M.P.H., M.S.C.S., Ofri Mosenzon, M.D., Sue D. Pedersen, M.D., Cees J. Tack, M.D., Mette Thomsen, M.D., D.M.Sc., et al., for the PIONEER 6 Investigators
Conroy R.M., Pyörälä K., Fitzgerald A.P. i wsp. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur. Heart J. 2003; 24: 987–1003
How to Cite
Copyright (c) 2022 Kamil Pondel, Kinga Kawałko, Krzysztof Bielewicz, Anna Chmura, Anna Karaś
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Number of views and downloads: 83
Number of citations: 0